Holen Sie sich die Stockscreener-App
85.78
0.35%
0.26
Schlusskurs vom Vortag:
$85.52
Offen:
$85.7
24-Stunden-Volumen:
143.16K
Relative Volume:
0.32
Marktkapitalisierung:
$1.93B
Einnahmen:
$747.40M
Nettoeinkommen (Verlust:
$-12.60M
KGV:
-111.59
EPS:
-0.7687
Netto-Cashflow:
$105.18M
1W Leistung:
+0.62%
1M Leistung:
+6.32%
6M Leistung:
+29.36%
1J Leistung:
+47.56%
1-Tages-Spanne:
$85.31
$86.97
1-Wochen-Bereich:
$83.03
$87.07
52-Wochen-Spanne:
$54.10
$99.50
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Firmenname
Ani Pharmaceuticals Inc
Sektor
Telefon
(218) 634-3500
Adresse
210 MAIN STREET WEST, BAUDETTE, MN
Vergleichen Sie ANIP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
85.72 | 1.92B | 747.40M | -12.60M | 105.18M | -0.7687 |
|
ZTS
Zoetis Inc
|
123.97 | 55.12B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.97 | 50.80B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.27 | 45.60B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.64 | 36.04B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
470.64 | 20.23B | 3.08B | 1.24B | 1.07B | 25.61 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-14 | Eingeleitet | Jefferies | Buy |
| 2025-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2024-12-11 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-15 | Eingeleitet | CapitalOne | Overweight |
| 2023-08-22 | Bestätigt | H.C. Wainwright | Buy |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-09-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-02 | Eingeleitet | Truist | Buy |
| 2020-05-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-05-10 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2017-10-16 | Bestätigt | Canaccord Genuity | Buy |
| 2017-07-31 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-02-22 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2016-06-23 | Eingeleitet | Raymond James | Strong Buy |
| 2016-05-24 | Herabstufung | Standpoint Research | Buy → Hold |
| 2015-11-13 | Eingeleitet | Standpoint Research | Buy |
| 2015-09-28 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2015-08-05 | Bestätigt | Oppenheimer | Outperform |
| 2015-08-04 | Bestätigt | ROTH Capital | Neutral |
| 2015-07-31 | Bestätigt | Oppenheimer | Outperform |
| 2015-07-15 | Bestätigt | ROTH Capital | Neutral |
| 2015-06-23 | Bestätigt | Oppenheimer | Outperform |
| 2015-05-18 | Bestätigt | ROTH Capital | Neutral |
| 2015-05-06 | Bestätigt | Oppenheimer | Outperform |
| 2015-04-10 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2015-02-26 | Bestätigt | ROTH Capital | Buy |
| 2015-02-18 | Bestätigt | Oppenheimer | Outperform |
Alle ansehen
Ani Pharmaceuticals Inc Aktie (ANIP) Neueste Nachrichten
40 Under 40: Kevin Chan, ANI Pharmaceuticals - Medical Marketing and Media
Breakout Move: Does ANI Pharmaceuticals Inc stock have upside surprise potential - baoquankhu1.vn
ANI Pharmaceuticals, Inc. $ANIP Shares Sold by Mizuho Markets Americas LLC - MarketBeat
Aug Setups: What is the next catalyst for SEALPRAQuarterly Earnings Report & Technical Pattern Based Signals - baoquankhu1.vn
Campbell & CO Investment Adviser LLC Invests $1.60 Million in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals (ANIP) Is Up 11.2% After Raising 2026 Revenue Outlook And Rare Disease Hiring Plan – Has The Bull Case Changed? - Sahm
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
ANIP vs. TEVA: Which Drug Stock Is the Better Buy Right Now? - Eastern Progress
ANIP Stock Rises 7% in a Week: Here's What You Should Know - Eastern Progress
Guggenheim Reaffirms Their Buy Rating on ANI Pharmaceuticals (ANIP) - The Globe and Mail
SG Americas Securities LLC Boosts Stock Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals (ANIP) Is Up 7.0% After Raising 2026 Revenue Outlook and Expanding Rare Disease Team - Yahoo Finance
Insider Sell Alert: Meredith Cook Sells Shares of ANI Pharmaceuticals Inc (ANIP) - GuruFocus
Ani Pharmaceuticals’ Cook sells $42,165 in stock By Investing.com - Investing.com Australia
Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) VP Sells 500 Shares of Stock - MarketBeat
Ani Pharmaceuticals’ Cook sells $42,165 in stock - Investing.com
ANI Pharmaceuticals Targets $1B+ 2026 Revenue as Rare Disease Pivot Accelerates, Cortrophin Leads Growth - Yahoo Finance
ANI Pharmaceuticals (ANIP) Stock Dips on Profit-Taking After 2026 GuidanceNews and Statistics - IndexBox
ANI Pharmaceuticals (ANIP) Stock Trades Down, Here Is Why - Finviz
ANI Pharmaceuticals: Strong 2025 Finish And Bullish 2026 Guidance (NASDAQ:ANIP) - Seeking Alpha
Stocks making big moves yesterday: OneMain, Nextpower, ANI Pharmaceuticals, Akamai Technologies, and Lemonade - The Globe and Mail
Growth Review: Can ANI Pharmaceuticals Inc. stock deliver consistent earnings growth2025 Performance Recap & Stepwise Trade Signal Implementation - Bộ Nội Vụ
Fund Flows: Why ANI Pharmaceuticals Inc stock remains undervaluedEarnings Risk Summary & Low Risk Entry Point Guides - Bộ Nội Vụ
ANI Pharmaceuticals, Inc. (ANIP) Investor Outlook: Exploring a 29.52% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Decker Retirement Planning Inc. Boosts Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals expects over $1 billion in 2026 revenue By Investing.com - Investing.com Nigeria
Why ANI Pharmaceuticals (ANIP) Stock Is Trading Up Today - Finviz
The Sun: Local News, Sports and Things to DoWhy ANI Pharmaceuticals (ANIP) Stock Is Trading Up Today - FinancialContent
ANI Pharmaceuticals (NASDAQ:ANIP) Shares Gap UpTime to Buy? - MarketBeat
Ani Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2026 - marketscreener.com
ANI Pharmaceuticals (NASDAQ:ANIP) Updates FY 2025 Earnings Guidance - MarketBeat
ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities - The Manila Times
ANI Pharmaceuticals expects over $1 billion in 2026 revenue - Investing.com
ANI Pharma is building a 90-person rare disease team for gout flares in 2026 - Stock Titan
ANI Pharmaceuticals (ANIP) Valuation Check After Robust 2025 Results And Raised Guidance - Sahm
How ANI Pharmaceuticals Inc. stock performs in weak economyWeekly Stock Summary & Risk Adjusted Buy/Sell Alerts - Улправда
ANI Pharmaceuticals (NASDAQ:ANIP) Trading Down 6.3%Time to Sell? - MarketBeat
Momentum Shift: How ANI Pharmaceuticals Inc. stock performs in weak economyTrade Entry Summary & High Return Trade Guides - Улправда
How ANI Pharmaceuticals Inc. (BSFA) stock trades pre earningsPortfolio Performance Report & Fast Momentum Entry Tips - Улправда
Do Strong 2025 Rare Disease Results Reshape the Bull Case for ANI Pharmaceuticals (ANIP)? - Sahm
How ANI Pharmaceuticals Inc. stock reacts to global recession fears2025 Growth vs Value & Reliable Breakout Stock Forecasts - ulpravda.ru
Is ANI Pharmaceuticals Inc. (BSFA) stock a defensive play amid uncertainty2025 EndofYear Setup & Expert Verified Stock Movement Alerts - ulpravda.ru
What earnings margins imply for ANI Pharmaceuticals Inc. (BSFA) stockJuly 2025 Spike Watch & Consistent Return Investment Signals - ulpravda.ru
ANI Pharmaceuticals (NASDAQ:ANIP) Lowered to "Hold" Rating by Zacks Research - MarketBeat
ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - Sahm
Is ANI Pharmaceuticals (ANIP) Price Justified After Updated 2025 Revenue Guidance? - Yahoo Finance
ANI Pharmaceuticals, Inc. CEO Nikhil Lalwani to Present at 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
ANIP Up 21% in 6 Months: Is It Worth Investing in the Stock Now? - Your Wyoming Link
ANI Pharmaceuticals, Inc. (ANIP) Stock Analysis: A Healthcare Gem with 38.89% Upside Potential - DirectorsTalk Interviews
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
3 Reasons to Avoid ANIP and 1 Stock to Buy Instead - Finviz
Finanzdaten der Ani Pharmaceuticals Inc-Aktie (ANIP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ani Pharmaceuticals Inc-Aktie (ANIP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Davis Krista | SVP, CHIEF HR OFFICER |
Dec 18 '25 |
Sale |
82.40 |
1,622 |
133,653 |
58,564 |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. |
Dec 12 '25 |
Sale |
82.32 |
400 |
32,928 |
74,874 |
| TANNENBAUM RENEE P | Director |
Dec 05 '25 |
Sale |
81.15 |
1,800 |
146,070 |
25,157 |
3.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):